San Diego – April 23, 2014 – Cooley LLP announced today that it advised the underwriters on Vital Therapies, Inc.'s initial public offering. Vital Therapies is a biotherapeutic company that is developing a cell-based therapy targeting the treatment of acute liver failure. It now trades on the NSADAQ Global Stock Market under the symbol "VTL."
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. William Blair & Company, L.L.C. and Canaccord Genuity Inc. acted as co-managers.
The Cooley corporate and securities team advising the underwriters was led by partners Tom Coll, Charlie Kim and Sean Clayton, and included associates Veer Bhavnagri, Kristin VanderPas, Rebecca Jones and Dani Nazemian. Critical support for the offering was provided by partner Bill Christiansen (intellectual property); partner Amy Wood, special counsel Jeannie Leahy and associate Megan Arthur (compensation & benefits); partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell, associates Jennifer Shanley and Leah Roffman (regulatory); and partner Susan Cooper Philpot (tax).
Year-to-date in 2014, Cooley has advised on 47 completed public offerings, including 24 completed IPOs.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.